A Rapid psychoactive action of Rapastinel free of psychomimetic symptoms

Unveiling Anti-Inflammatory Efficacy: The Power of the Carrageenan Air Pouch Model

Newsletter # 124



In vivo studies


Inflammation underpins many debilitating diseases—from arthritis to acute systemic conditions—driving the need for effective, targeted therapies. The 24-hour carrageenan air pouch model in mice, originally developed to simulate synovial inflammation, provides a robust and translationally relevant platform to support this pursuit.
This sophisticated in-vivo model stands out as a reliable, quantifiable system for evaluating anti-inflammatory drug efficacy. Its key features offer actionable insights into both inflammatory mechanisms and therapeutic impact:
The Neurofit investigations revealed that:
Robust Inflammatory Response:
Consistently induces significant cellular infiltration, including granulocytes (GRAN also known as Polymorphonuclear), lymphocytes (LYMP) and monocytes (MON)—mimicking complex tissue-level inflammation.
Quantifiable Molecular Endpoints:
Elevated pro-inflammatory cytokines offer precise molecular readouts to monitor therapeutic modulation.
Clear Pharmacological Sensitivity:
The model responds robustly to corticosteroid treatment. Dexamethasone significantly reduces inflammation, normalizing immune cell counts and cytokine levels. This effect is often visualized as a clear drop in the "Dexamethasone-treated" group (grey column) compared to the placebo-treated group (blue column), with the inflammation-free control group (orange column) providing a baseline reference. With its well-defined cellular and molecular parameters, and strong alignment with clinical inflammation profiles, the carrageenan air pouch model is an ideal system for screening and validating novel anti-inflammatory agents.
With its well-defined cellular and molecular parameters, and strong alignment with clinical inflammation profiles, the carrageenan air pouch model is an ideal system for screening and validating novel anti-inflammatory agents.
  • NEUROFIT website

    NEUROFIT website

    Values are expressed as mean ± standard error of the mean (SEM). *, *** denote statistically significant differences between treatment groups, as compared to Carrageenan + placebo-treated group.
    Orange column: Non-inflamed control group,
    Blue column: Carrageenan + placebo-treated group,
    Grey column: Carrageenan + dexamethasone-treated group

    Leukocyte Subpopulations: GRAN: Granulocytes (Polymorphonuclear cells), LYMP: Lymphocytes, MON: Monocytes


NEUROFIT offers a range of validated in vitro and in vivo screening tests for psychiatry and neurology.

If you need further information, please do not hesitate to contact us, we will reply within few days. Custom protocol

On a regular basis we distribute newsletters with scientific information on our research services. If you wish to receive these, please :